HLA-C and neoplasm: Tumor cells may down-regulate their major histocompatibility complex (MHC) expression to evade recognition and elimination by T cells, whereas NK cells can attack those tumor cells with abnormal MHC expression, making them a potent candidate for ACT with a lower risk of graft-versus-host adverse events [17,18].